Diamond Therapeutics

Diamond is pleased to announce a strategic investment round led by First Avenue Ventures Life Science Fund I. newswire.ca/news-releases/…

@uabnews and @DiamondThera have announced a collaboration, researching low doses of psilocybin to treat demoralization. @uabsoph professor Peter Hendricks, PhD is principle investigator in this five-week randomized clinical trial. Read more at go.uab.edu/40lKYXZ

Diamond is excited to announce our FDA-authorized clinical trial of low-dose psilocybin in collaboration with the University of Alabama at Birmingham. newswire.ca/news-releases/…

@afelicelli @WovenScience Hi Antoine. We want to DM you a contact email.

@WovenScience @DiamondThera Hello, i ve been trying to reach by email wihtout success so far... Can someone reach out please ? I represent one of your investors. Thank you

Our portfolio company @DiamondThera completes Phase I clinical study of low-dose #psilocybin in healthy human subjects psychedelicinvest.com/diamond-therap… #clinicaltrials #psychedelicresearch

“Anxiety is the most common psychiatric disorder,” says Judy Blumstock, Diamond’s chief executive. “And the existing treatments aren’t satisfactory.” thestar.com/business/mars/…

Today is #BellLetsTalk Day! One of the ways we can all take action is to learn about mental health organizations creating positive change for mental health in Canada…every day.

Diamond’s Phase 2 trial has been approved by Health Canada, a Phase 2 randomized, double-blind study in adult patients with Generalized Anxiety Disorder. Patients will receive repeat low doses of psilocybin administered on a take-home basis. @DiamondThera bit.ly/4048ppA

Diamond has received Health Canada approval to begin a Phase 2 clinical trial evaluating the safety, tolerability and efficacy of repeat low doses of psilocybin for the treatment of generalized anxiety disorder (GAD). lnkd.in/g3KpXHQU

Thank you, Roland Griffiths, for all you've done and continue to do to advance psychedelic science.

“The purpose of this endowment is to support a professorship and to establish a world class, rigorous, empirical program of research with psychedelic substances..”griffithsfund.org

Excited to see our Phase 1 trial results and the potential for take-at-home psychedelic-derived drugs covered by Benzinga! benzinga.com/markets/cannab…

Read the full release here: newswire.ca/news-releases/…

And thanks to Chef for this whimsical dessert!

Thank you, Dr. Emma Hapke, Dr. Daniel Rosenbaum, Dr. Susan Abbey, Nikean Foundation and @uhnfoundation, for a lively evening at The York Club.

Diamond CEO Judy Blumstock discusses all things low-dose psilocybin with The Tonic. thetonic.ca/articles/healt…

Exciting news. Wishing all GEEKs much success!!

New episode: Microdosing (Part 3)! We discuss the path to FDA approval with... Dr. Dan Karlin: MindMed (LSD for adult ADHD) and Dr. Mike McDonnell: Diamond Therapeutics (psilocybin for anxiety disorders) Tune in here: businesstrip.fm/podcast/episod… @mindmedco @DiamondThera

For those looking for more information about psychedelics and psychedelic therapy, check out the Berkeley Center’s new resources website, psychedelics.berkeley.edu

In part 2 (out next week), we discuss the placebo effect and results from a placebo controlled microdosing study from @psybalazs @imperialcollege. In part 3, we talk w/ the chief medical officers of @mindmedco @DiamondThera about going for FDA approval for microdosing.

5/5 @DiamondThera science advisory chair Dr. Ed Sellers outlines the challenges of testing #psychedelics in human subjects in the International Journal of Pharmacology’s special issue on psychedelic science. sciencedirect.com/science/articl…

4/5 In this episode of @ProfDavidNutt's @Drug_Science Podcast, @DiamondThera advisor Dr. Paul Glue discusses the development of oral ketamine and his hope that it can become an at-home vs. in-clinic treatment. youtube.com/watch?v=XPrR19…

1/5 If you’re enjoying @michaelpollan’s #HowToChangeYourMind on @netflix and want to go deeper on the science, here’s a list of #psychedelic readings authored by @DiamondThera advisors, collaborators and team members: